Medicare Part D covers Ozempic and Mounjaro for type 2 diabetes But does not currently cover Wegovy or Zepbound for weight loss alone. A proposed CMS rule may expand GLP-1 coverage for obesity — but it has not been finalized. If you use these drugs for diabetes, your cost is subject to your plan's formulary tier and the new $2,100 annual out-of-pocket cap.
In this article
If you're one of the millions of Americans over 65 taking — or considering — a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, you're almost certainly wondering what Medicare will pay for. These drugs can cost over $1,000 per month at retail price, making coverage a very high-stakes question.
The short version: Medicare's coverage depends entirely on why the drug is prescribed. The same molecule can be covered or not covered depending on whether your diagnosis is diabetes or obesity. This article breaks down exactly where coverage stands in 2026 and what your options are if Medicare won't pay.
What Are GLP-1 Drugs?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a hormone your gut releases after eating. They were originally developed to treat type 2 diabetes by stimulating insulin release and slowing gastric emptying. A notable side effect turned out to be significant weight loss — which led to FDA approvals of higher-dose versions specifically for obesity.
The major GLP-1 drugs you'll hear about are:
- Ozempic (semaglutide 0.5mg, 1mg, 2mg) — FDA-approved for type 2 diabetes
- Wegovy (semaglutide 2.4mg) — FDA-approved for chronic weight management
- Mounjaro (tirzepatide 5mg–15mg) — FDA-approved for type 2 diabetes
- Zepbound (tirzepatide 5mg–15mg) — FDA-approved for chronic weight management
- Victoza / Saxenda (liraglutide) — older GLP-1; Victoza for diabetes, Saxenda for weight loss
- Rybelsus (oral semaglutide) — FDA-approved for type 2 diabetes (pill form)
The active ingredient in Ozempic and Wegovy is the same (semaglutide). The difference is the dose and the FDA-approved indication — which is exactly what determines Medicare coverage.
Does Medicare Cover Ozempic in 2026?
Yes — when prescribed for type 2 diabetes.
Ozempic (semaglutide) is an FDA-approved treatment for type 2 diabetes, and Medicare Part D plans are required to cover anti-diabetic agents. Most Part D plans include Ozempic on their formulary, though the tier placement — and therefore your copay — varies by plan.
The critical condition: your prescription must be for type 2 diabetes management. If a doctor writes "obesity" or "weight management" as the diagnosis on a prescription for Ozempic, your Part D plan will likely deny coverage. Medicare's rules prohibit coverage of drugs used solely for weight loss, and the denial can come at the pharmacy counter.
Most Part D plans place Ozempic on Tier 3 (preferred brand), which typically means a copay of $40–$100 per month after your deductible. Some plans place it on Tier 4 (non-preferred brand), which can mean $80–$150 or a coinsurance percentage. The specific amount depends entirely on your plan.
Does Medicare Cover Wegovy in 2026?
No — not under current federal law.
Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management in adults with a BMI of 30+ or 27+ with a weight-related condition. It is the same drug as Ozempic at a higher dose, but its approved indication is weight loss, not diabetes.
Federal law — specifically the Social Security Act — explicitly prohibits Medicare Part D from covering drugs used for "anorexia, weight loss, or weight gain." This prohibition applies regardless of which drug it is or what the FDA has approved it for. Because Wegovy's approved use is weight management, it falls squarely under this exclusion.
The one exception: if a physician prescribes Wegovy off-label for a patient with documented type 2 diabetes who hasn't responded to lower-dose semaglutide, coverage may be possible depending on the plan — but this is not standard and requires prior authorization.
Does Medicare Cover Mounjaro and Zepbound?
The same split applies to tirzepatide:
- Mounjaro (diabetes indication) — Covered by most Part D plans
- Zepbound (obesity indication) — Not covered under current Medicare rules
Mounjaro has shown strong results in clinical trials — producing greater A1C reductions than most older diabetes drugs — so physicians frequently prescribe it, and Part D formularies have widely adopted it. Expect Tier 3 or Tier 4 placement depending on your specific plan.
Zepbound, Eli Lilly's weight-loss branded version of tirzepatide, launched in late 2023 and is not covered by Medicare Part D under the current statutory prohibition on weight-loss drugs.
GLP-1 Medicare Coverage at a Glance (2026)
| Drug | Brand | Approved Use | Part D Coverage | Typical Tier |
|---|---|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes | ✓ Covered | Tier 3–4 |
| Semaglutide 2.4mg | Wegovy | Weight loss | ✗ Not covered | — |
| Oral semaglutide | Rybelsus | Type 2 diabetes | ✓ Covered | Tier 3–4 |
| Tirzepatide | Mounjaro | Type 2 diabetes | ✓ Covered | Tier 3–4 |
| Tirzepatide | Zepbound | Weight loss | ✗ Not covered | — |
| Liraglutide | Victoza | Type 2 diabetes | ✓ Covered | Tier 2–3 |
| Liraglutide 3mg | Saxenda | Weight loss | ✗ Not covered | — |
| Dulaglutide | Trulicity | Type 2 diabetes | ✓ Covered | Tier 3 |
| Exenatide ER | Bydureon BCise | Type 2 diabetes | ✓ Covered | Tier 3–4 |
What You'll Pay With Medicare Coverage (2026)
If your GLP-1 drug is covered under Part D for diabetes, here's what your cost structure looks like in 2026:
| Phase | How It Works | Your Cost |
|---|---|---|
| Deductible | You pay 100% until you meet the annual deductible | Up to $590 (2026 standard deductible) |
| Initial coverage | You pay your plan's copay or coinsurance | $40–$150/month depending on tier |
| Catastrophic cap | Once you've spent $2,100 out-of-pocket, you pay $0 | $0 for the rest of the year |
The new $2,100 annual out-of-pocket cap (introduced in 2025 under the Inflation Reduction Act) is a major benefit for GLP-1 users who previously faced unlimited drug costs. Once your total Part D spending hits $2,100 for the year, your plan covers 100% of covered drug costs for the remainder of the year.
What If Medicare Won't Cover Your GLP-1?
If you're taking Wegovy or Zepbound for weight loss and Medicare won't cover it, you have several options:
1. Manufacturer Patient Assistance Programs
Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) both offer savings programs for eligible patients. Income limits apply. Visit the manufacturer's website or ask your doctor's office.
2. GoodRx and Discount Programs
GoodRx and similar discount programs sometimes offer lower prices than Medicare cost-sharing for certain drugs, especially if your plan has placed the drug on a high tier. Compare your Medicare cost to GoodRx pricing — but remember you cannot use both simultaneously for the same prescription.
3. Compounded Semaglutide or Tirzepatide
Some telehealth pharmacies have offered compounded versions of semaglutide or tirzepatide at lower prices. As of 2025–2026, FDA has taken action against certain compounders as the name-brand shortage has eased. Compounded drugs are not FDA-approved and carry their own risks. Discuss with your physician before using any compounded GLP-1.
4. Appeal Your Plan's Denial
If your plan denied coverage for Ozempic or Mounjaro for diabetes — not weight loss — you have the right to appeal. Request a formulary exception or coverage determination through your plan. Your doctor can support the appeal with clinical documentation.
Will Medicare Ever Cover GLP-1s for Weight Loss?
Possibly — and soon. In November 2023, CMS published a proposed rule that would reinterpret the weight-loss drug exclusion to allow Part D coverage of GLP-1 drugs when used to treat obesity as a chronic disease. The proposal cited growing evidence that obesity is a metabolic condition, not merely a lifestyle issue.
As of early 2026, the rule has not been finalized. If finalized, it could make Wegovy and Zepbound eligible for Part D coverage — though plans would still have discretion over which drugs to include on their formularies.
Check Medicare.gov and CMS.gov for the latest rulemaking updates, or subscribe to SeniorAffair.com's newsletter for coverage alerts.
Need help comparing Medicare Part D plans?
A licensed Medicare specialist can show you which plans in your area cover your diabetes medications at the lowest cost.
Get a Free Plan Comparison →Frequently Asked Questions
Does Medicare cover Ozempic in 2026?
Yes — Medicare Part D covers Ozempic when prescribed for type 2 diabetes. It does not cover Ozempic when prescribed solely for weight loss. Most plans place it on Tier 3 or Tier 4, with copays typically ranging from $40–$150 per month after your deductible.
Does Medicare cover Wegovy for weight loss in 2026?
No. Medicare Part D does not cover Wegovy for obesity or weight management under current federal law. A CMS proposed rule could change this, but as of 2026 it has not been finalized.
Does Medicare cover Mounjaro or Zepbound?
Medicare Part D covers Mounjaro for type 2 diabetes. Zepbound, the same drug marketed for weight loss, is not covered under current rules.
How much does Ozempic cost with Medicare?
If your Part D plan covers Ozempic, typical costs are $40–$150 per month after your deductible. Under the 2026 $2,100 annual out-of-pocket cap, your total drug spending cannot exceed $2,100 for the year — after that, Medicare pays 100%.
Can I get GLP-1 drugs cheaper without Medicare?
Sometimes — but mixing Medicare with manufacturer coupons on a covered drug can jeopardize your Part D coverage. Consult your pharmacist before using any outside discount programs for Part D-covered medications.
What if my Part D plan denies Ozempic for diabetes?
You have the right to appeal. Request a coverage determination or formulary exception through your plan. Your physician can provide clinical documentation supporting the diabetes diagnosis to strengthen the appeal.
